Financhill
Sell
24

ESPR Quote, Financials, Valuation and Earnings

Last price:
$0.80
Seasonality move :
-8.15%
Day range:
$0.75 - $0.81
52-week range:
$0.69 - $3.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.60x
P/B ratio:
--
Volume:
5M
Avg. volume:
6.4M
1-year change:
-69.04%
Market cap:
$158.9M
Revenue:
$332.3M
EPS (TTM):
-$0.80

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ESPR
Esperion Therapeutics
$54.2M -$0.15 -15.29% -42.42% $5.79
AMLX
Amylyx Pharmaceuticals
-- -$0.50 -100% -57.63% $10.80
HRTX
Heron Therapeutics
$37.4M -$0.01 5.3% -75% $6.33
OCUL
Ocular Therapeutix
$16.9M -$0.28 -20.3% -33.34% $17.50
PSTV
Plus Therapeutics
$1.1M -$0.29 -- -54.22% $9.83
XERS
Xeris Biopharma Holdings
$57.6M -$0.04 33.13% -70% $6.42
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ESPR
Esperion Therapeutics
$0.80 $5.79 $158.9M -- $0.00 0% 0.60x
AMLX
Amylyx Pharmaceuticals
$4.84 $10.80 $431.4M 21.03x $0.00 0% 4.02x
HRTX
Heron Therapeutics
$1.97 $6.33 $300.6M -- $0.00 0% 2.03x
OCUL
Ocular Therapeutix
$7.22 $17.50 $1.2B -- $0.00 0% 20.28x
PSTV
Plus Therapeutics
$0.42 $9.83 $7.1M -- $0.00 0% 0.52x
XERS
Xeris Biopharma Holdings
$4.79 $6.42 $767.1M -- $0.00 0% 3.22x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ESPR
Esperion Therapeutics
-219.93% 2.884 103.46% 0.72x
AMLX
Amylyx Pharmaceuticals
-- -0.377 -- 6.23x
HRTX
Heron Therapeutics
119.42% -0.701 52.18% 1.46x
OCUL
Ocular Therapeutix
20.65% 0.643 5.93% 9.89x
PSTV
Plus Therapeutics
-- -0.140 -- --
XERS
Xeris Biopharma Holdings
118.05% -1.328 26.83% 1.10x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ESPR
Esperion Therapeutics
$33.5M -$22.1M -- -- -32.35% -$22.6M
AMLX
Amylyx Pharmaceuticals
-- -$37.8M -109.32% -109.32% 6113.38% -$39.8M
HRTX
Heron Therapeutics
$30.4M $3.2M -5.57% -- 8.11% -$9M
OCUL
Ocular Therapeutix
$9.4M -$63.9M -46.82% -56.05% -570.85% -$46.6M
PSTV
Plus Therapeutics
-- -$3.8M -- -- -- -$3.7M
XERS
Xeris Biopharma Holdings
$51.4M -$3.1M -21.84% -1019.2% -3.19% -$10M

Esperion Therapeutics vs. Competitors

  • Which has Higher Returns ESPR or AMLX?

    Amylyx Pharmaceuticals has a net margin of -62.24% compared to Esperion Therapeutics's net margin of -17476.92%. Esperion Therapeutics's return on equity of -- beat Amylyx Pharmaceuticals's return on equity of -109.32%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESPR
    Esperion Therapeutics
    51.48% -$0.21 -$133.2M
    AMLX
    Amylyx Pharmaceuticals
    -94.47% -$0.42 $164.8M
  • What do Analysts Say About ESPR or AMLX?

    Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 621.59%. On the other hand Amylyx Pharmaceuticals has an analysts' consensus of $10.80 which suggests that it could grow by 123.14%. Given that Esperion Therapeutics has higher upside potential than Amylyx Pharmaceuticals, analysts believe Esperion Therapeutics is more attractive than Amylyx Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESPR
    Esperion Therapeutics
    2 2 0
    AMLX
    Amylyx Pharmaceuticals
    4 1 0
  • Is ESPR or AMLX More Risky?

    Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Amylyx Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ESPR or AMLX?

    Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amylyx Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Amylyx Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESPR or AMLX?

    Esperion Therapeutics quarterly revenues are $65M, which are larger than Amylyx Pharmaceuticals quarterly revenues of -$665K. Esperion Therapeutics's net income of -$40.5M is lower than Amylyx Pharmaceuticals's net income of -$35.9M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Amylyx Pharmaceuticals's PE ratio is 21.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.60x versus 4.02x for Amylyx Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESPR
    Esperion Therapeutics
    0.60x -- $65M -$40.5M
    AMLX
    Amylyx Pharmaceuticals
    4.02x 21.03x -$665K -$35.9M
  • Which has Higher Returns ESPR or HRTX?

    Heron Therapeutics has a net margin of -62.24% compared to Esperion Therapeutics's net margin of 6.77%. Esperion Therapeutics's return on equity of -- beat Heron Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ESPR
    Esperion Therapeutics
    51.48% -$0.21 -$133.2M
    HRTX
    Heron Therapeutics
    78.26% $0.02 $146.5M
  • What do Analysts Say About ESPR or HRTX?

    Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 621.59%. On the other hand Heron Therapeutics has an analysts' consensus of $6.33 which suggests that it could grow by 221.49%. Given that Esperion Therapeutics has higher upside potential than Heron Therapeutics, analysts believe Esperion Therapeutics is more attractive than Heron Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESPR
    Esperion Therapeutics
    2 2 0
    HRTX
    Heron Therapeutics
    2 0 0
  • Is ESPR or HRTX More Risky?

    Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Heron Therapeutics has a beta of 1.328, suggesting its more volatile than the S&P 500 by 32.785%.

  • Which is a Better Dividend Stock ESPR or HRTX?

    Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Heron Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Heron Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESPR or HRTX?

    Esperion Therapeutics quarterly revenues are $65M, which are larger than Heron Therapeutics quarterly revenues of $38.9M. Esperion Therapeutics's net income of -$40.5M is lower than Heron Therapeutics's net income of $2.6M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Heron Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.60x versus 2.03x for Heron Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESPR
    Esperion Therapeutics
    0.60x -- $65M -$40.5M
    HRTX
    Heron Therapeutics
    2.03x -- $38.9M $2.6M
  • Which has Higher Returns ESPR or OCUL?

    Ocular Therapeutix has a net margin of -62.24% compared to Esperion Therapeutics's net margin of -598.74%. Esperion Therapeutics's return on equity of -- beat Ocular Therapeutix's return on equity of -56.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESPR
    Esperion Therapeutics
    51.48% -$0.21 -$133.2M
    OCUL
    Ocular Therapeutix
    88.2% -$0.38 $335.1M
  • What do Analysts Say About ESPR or OCUL?

    Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 621.59%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 142.38%. Given that Esperion Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Esperion Therapeutics is more attractive than Ocular Therapeutix.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESPR
    Esperion Therapeutics
    2 2 0
    OCUL
    Ocular Therapeutix
    6 0 0
  • Is ESPR or OCUL More Risky?

    Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.759%.

  • Which is a Better Dividend Stock ESPR or OCUL?

    Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESPR or OCUL?

    Esperion Therapeutics quarterly revenues are $65M, which are larger than Ocular Therapeutix quarterly revenues of $10.7M. Esperion Therapeutics's net income of -$40.5M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.60x versus 20.28x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESPR
    Esperion Therapeutics
    0.60x -- $65M -$40.5M
    OCUL
    Ocular Therapeutix
    20.28x -- $10.7M -$64.1M
  • Which has Higher Returns ESPR or PSTV?

    Plus Therapeutics has a net margin of -62.24% compared to Esperion Therapeutics's net margin of --. Esperion Therapeutics's return on equity of -- beat Plus Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ESPR
    Esperion Therapeutics
    51.48% -$0.21 -$133.2M
    PSTV
    Plus Therapeutics
    -- -$0.37 --
  • What do Analysts Say About ESPR or PSTV?

    Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 621.59%. On the other hand Plus Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 2241.27%. Given that Plus Therapeutics has higher upside potential than Esperion Therapeutics, analysts believe Plus Therapeutics is more attractive than Esperion Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESPR
    Esperion Therapeutics
    2 2 0
    PSTV
    Plus Therapeutics
    1 1 0
  • Is ESPR or PSTV More Risky?

    Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.878, suggesting its less volatile than the S&P 500 by 12.185%.

  • Which is a Better Dividend Stock ESPR or PSTV?

    Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESPR or PSTV?

    Esperion Therapeutics quarterly revenues are $65M, which are larger than Plus Therapeutics quarterly revenues of --. Esperion Therapeutics's net income of -$40.5M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.60x versus 0.52x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESPR
    Esperion Therapeutics
    0.60x -- $65M -$40.5M
    PSTV
    Plus Therapeutics
    0.52x -- -- -$2.9M
  • Which has Higher Returns ESPR or XERS?

    Xeris Biopharma Holdings has a net margin of -62.24% compared to Esperion Therapeutics's net margin of -15.34%. Esperion Therapeutics's return on equity of -- beat Xeris Biopharma Holdings's return on equity of -1019.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESPR
    Esperion Therapeutics
    51.48% -$0.21 -$133.2M
    XERS
    Xeris Biopharma Holdings
    85.48% -$0.06 $194.6M
  • What do Analysts Say About ESPR or XERS?

    Esperion Therapeutics has a consensus price target of $5.79, signalling upside risk potential of 621.59%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.42 which suggests that it could grow by 33.96%. Given that Esperion Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Esperion Therapeutics is more attractive than Xeris Biopharma Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESPR
    Esperion Therapeutics
    2 2 0
    XERS
    Xeris Biopharma Holdings
    4 1 0
  • Is ESPR or XERS More Risky?

    Esperion Therapeutics has a beta of 0.749, which suggesting that the stock is 25.126% less volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.36%.

  • Which is a Better Dividend Stock ESPR or XERS?

    Esperion Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESPR or XERS?

    Esperion Therapeutics quarterly revenues are $65M, which are larger than Xeris Biopharma Holdings quarterly revenues of $60.1M. Esperion Therapeutics's net income of -$40.5M is lower than Xeris Biopharma Holdings's net income of -$9.2M. Notably, Esperion Therapeutics's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics is 0.60x versus 3.22x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESPR
    Esperion Therapeutics
    0.60x -- $65M -$40.5M
    XERS
    Xeris Biopharma Holdings
    3.22x -- $60.1M -$9.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Newegg Commerce Up So Much?
Why Is Newegg Commerce Up So Much?

Consumer electronics eCommerce store Newegg (NASDAQ:NEGG) has staged a dramatic…

Is Unity Software a Buy Now?
Is Unity Software a Buy Now?

Unity Software (NYSE:U) is the company behind the popular Unity…

Will Uber Stock 5X?
Will Uber Stock 5X?

Uber (NYSE:UBER) has generated extremely strong returns for its investors…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
81
SMLR alert for May 17

Semler Scientific [SMLR] is up 28.56% over the past day.

Sell
25
GLOB alert for May 17

Globant SA [GLOB] is down 23.54% over the past day.

Buy
94
HIMS alert for May 17

Hims & Hers Health [HIMS] is up 10.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock